Skip to main content
. 2019 Sep 16;2019:3143469. doi: 10.1155/2019/3143469

Table 2.

Comparison of secondary outcome measures.

Items Groups V0 V1 V2 V3 V4 p
CFS score Treatment group 6.02 ± 3.74 2.86 ± 2.83 2.52 ± 2.38 2.05 ± 2.23 0.67 ± 1.07 <0.001
Control group 6.14 ± 4.44 3.50 ± 2.82 3.82 ± 3.35 2.82 ± 2.92 1.14 ± 1.64 <0.001
p # 0.915 0.391 0.078 0.243 0.173

NIKBUT Treatment group 7.38 ± 5.79 7.44 ± 4.14 9.14 ± 4.97 10.71 ± 4.04 12.07 ± 4.14 <0.001
Control group 7.10 ± 5.61 7.17 ± 4.16 8.73 ± 4.95 9.23 ± 4.06 10.53 ± 4.48 0.085
p # 0.857 0.803 0.759 0.168 0.175

OSDI score Treatment group 35.38 ± 15.76 22.08 ± 12.94 16.03 ± 9.54 8.18 ± 8.01 6.89 ± 7.61 <0.001
Control group 44.76 ± 17.06 31.62 ± 15.89 22.32 ± 8.97 14.84 ± 7.32 12.05 ± 4.64 <0.001
p # 0.130 0.077 0.081 0.029 0.049

SIT Treatment group 7.31 ± 5.24 6.81 ± 4.49 7.93 ± 4.19 8.26 ± 3.91 8.93 ± 3.62 0.197
Control group 8.36 ± 5.17 5.91 ± 2.71 7.77 ± 2.74 7.64 ± 3.05 8.09 ± 3.31 0.168
p # 0.445 0.393 0.875 0.516 0.370

Classification of tear film lipid layer Treatment group 2.67 ± 0.85 2.93 ± 0.87 2.71 ± 0.80 2.64 ± 0.91 2.45 ± 0.83 0.155
Control group 2.86 ± 0.83 2.91 ± 0.75 2.59 ± 0.80 2.59 ± 0.67 2.45 ± 0.51 0.175
p # 0.377 0.929 0.561 0.813 0.991

Meibomian gland dropout (upper eyelid) Treatment group 2.14 ± 0.84 2.45 ± 0.63 2.60 ± 0.63 2.50 ± 0.63 2.38 ± 0.73 0.044
Control group 2.59 ± 0.67 2.45 ± 0.67 2.55 ± 0.51 2.55 ± 0.60 2.41 ± 0.59 0.857
p # 0.035 0.990 0.750 0.782 0.877

Meibomian gland dropout (lower eyelid) Treatment group 2.17 ± 0.82 2.45 ± 0.55 2.64 ± 0.62 2.48 ± 0.71 2.57 ± 0.59 0.016
Control group 2.82 ± 0.39 2.55 ± 0.51 2.73 ± 0.46 2.32 ± 0.72 2.68 ± 0.48 0.062
p # 0.001 0.512 0.574 0.401 0.452

p value of one-way repeated measure analysis of variance to compare data for each group at different time points; #p value of multivariate analysis to compare the treatment and control groups at a specific time point.